EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta‐analysis

Abdullah Ali Aljalfan, Muhammad Talha Maniya, Dilshad Sachedina, Serene Raaed Almuhaidib, Abdulmajeed Sulaiman Alharbi, Rahmah Alamrie, Umna Aziz, Anusha Abdul Muqeet Farid iD

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70084 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Abdullah Ali Aljalfan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, King Fahad University Hospital, Al Khobar, Saudi Arabia. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives As biologic therapy is increasingly being utilized in the treatment of paediatric psoriasis, we aim to perform a systematic review and network meta‐analysis to compare the efficacy and safety of available biologic treatments for moderate to severe paediatric plaque psoriasis.

Methods

Relevant randomized controlled trials (RCTs) were searched for in PubMed, Embase, Cochrane CENTRAL and clinicaltrials.gov . We performed a fixed‐effects frequentist network meta‐analysis (NMA) with the surface under the cumulative ranking curve (SUCRA) calculated for and mean ranking calculated. The main outcomes of interest were a ≥75% improvement in PASI score (PASI75), ≥90% improvement in PASI score (PASI90), 100% improvement in PASI score (PASI100), CDLQI score of 0/1 (CDLQI 0/1) at weeks 12–16 and safety outcomes at 12–20 weeks. Point probabilities of response were also calculated, presented as absolute risk differences per 1000 patients with their 95% CIs compared to placebo.

Results

Seven RCTs comprising 1016 psoriasis patients were included. Compared to placebo, all biologic therapies exhibited a significantly higher PASI90 and PASI75 response. Based on the SUCRA, Ixekizumab ranked highest in achieving the PASI100 (SUCRA: 0.9, Mean Rank: 1.8) response. Secukinumab high dose ranked the best for PASI90 (SUCRA: 0.8, Mean Rank: 3.0). For the CDLQI 0/1 (SUCRA: 0.8, Mean Rank: 2.2) response and the PASI75 (SUCRA: 0.9, Mean Rank: 2.2) response, standard dose Ustekinumab exhibited superior performance.

Conclusions

All biologic agents (not including non‐biologic comparators methotrexate and FAEs) were significantly superior to placebo, with no significant difference between individual biologic therapies, for the treatment of moderate‐to‐severe paediatric plaque psoriasis. Ixekizumab and Secukinumab demonstrated a trend towards a higher PASI90 response, while Ustekinumab showed a trend towards increased CDLQI and PASI75 responses. These findings highlight the need for better‐powered trials in this population to determine the optimal treatment modality. PROSPERO Number CRD42023476983.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsDermatologic AgentsHumansChildNetwork Meta-Analysis as TopicAntibodies, Monoclonal, HumanizedRandomized Controlled Trials as TopicUstekinumab

Stichwörter der Autor:innen

biologicsnetwork meta‐analysispaediatric psoriasispsoriasissystematic review

Substanzen

Biological ProductsAntibodies, Monoclonal, HumanizedUstekinumabDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, King Fahad University Hospital, Al Khobar, Saudi Arabia.
  • Department of Medicine, Ziauddin University, Karachi, Pakistan.
  • Department of Dermatology, Boston Medical Center, Boston, Massachusetts, USA.
  • College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Dermatology Department, Dammam Medical Complex, Dammam, Saudi Arabia.
  • Department of Medicine, Dow International Medical College, Karachi, Pakistan.

ORCID-Profile: Anusha Abdul Muqeet Farid

Zitieren

APA

Aljalfan, A. A., Maniya, M. T., Sachedina, D., Almuhaidib, S. R., Alharbi, A. S., Alamrie, R., Aziz, U., & Farid, A. A. M. (2026). Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta‐analysis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70084

Vancouver

Aljalfan AA, Maniya MT, Sachedina D, Almuhaidib SR, Alharbi AS, Alamrie R, et al. Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70084

BibTeX
@article{Aljalfan2026,
  author = {Aljalfan, Abdullah Ali and Maniya, Muhammad Talha and Sachedina, Dilshad and Almuhaidib, Serene Raaed and Alharbi, Abdulmajeed Sulaiman and Alamrie, Rahmah and Aziz, Umna and Farid, Anusha Abdul Muqeet},
  title = {Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta‐analysis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70084}
}
Kostenlos starten →